Literature DB >> 25795721

A magnetic resonance imaging-based prognostic scoring system to predict outcome in transplant-eligible patients with multiple myeloma.

Elias K Mai1, Thomas Hielscher2, Jost K Kloth3, Maximilian Merz1, Sofia Shah1, Marc S Raab1, Michaela Hillengass1, Barbara Wagner1, Anna Jauch4, Dirk Hose1, Marc-André Weber3, Stefan Delorme5, Hartmut Goldschmidt1, Jens Hillengass6.   

Abstract

Diffuse and focal bone marrow infiltration patterns detected by magnetic resonance imaging have been shown to be of prognostic significance in all stages of monoclonal plasma cell disorders and have, therefore, been incorporated into the definition of the disease. The aim of this retrospective analysis was to develop a rapidly evaluable prognostic scoring system, incorporating the most significant information acquired from magnetic resonance imaging. Therefore, the impact of bone marrow infiltration patterns on progression-free and overall survival in 161 transplant-eligible myeloma patients was evaluated. Compared to salt and pepper/minimal diffuse infiltration, moderate/severe diffuse infiltration had a negative prognostic impact on both progression-free survival (P<0.001) and overall survival (P=0.003). More than 25 focal lesions on whole-body magnetic resonance imaging or more than seven on axial magnetic resonance imaging were associated with an adverse prognosis (progression-free survival: P=0.001/0.003 and overall survival: P=0.04/0.02). A magnetic resonance imaging-based prognostic scoring system, combining grouped diffuse and focal infiltration patterns, was formulated and is applicable to whole-body as well as axial magnetic resonance imaging. The score identified high-risk patients with median progression-free and overall survival of 23.4 and 55.9 months, respectively (whole-body-based). Multivariate analyses demonstrated that the magnetic resonance imaging-based prognostic score stage III (high-risk) and adverse cytogenetics are independent prognostic factors for both progression-free and overall survival (whole-body-based, progression-free survival: hazard ratio=3.65, P<0.001; overall survival: hazard ratio=5.19, P=0.005). In conclusion, we suggest a magnetic resonance imaging-based prognostic scoring system which is a robust, easy to assess and interpret parameter summarizing significant magnetic resonance imaging findings in transplant-eligible patients with multiple myeloma. Copyright© Ferrata Storti Foundation.

Entities:  

Mesh:

Year:  2015        PMID: 25795721      PMCID: PMC4450628          DOI: 10.3324/haematol.2015.124115

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  30 in total

1.  Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p.

Authors:  Kai Neben; Henk M Lokhorst; Anna Jauch; Uta Bertsch; Thomas Hielscher; Bronno van der Holt; Hans Salwender; Igor W Blau; Katja Weisel; Michael Pfreundschuh; Christof Scheid; Ulrich Dührsen; Walter Lindemann; Ingo G H Schmidt-Wolf; Norma Peter; Christian Teschendorf; Hans Martin; Mathias Haenel; Hans G Derigs; Marc S Raab; Anthony D Ho; Helgi van de Velde; Dirk Hose; Pieter Sonneveld; Hartmut Goldschmidt
Journal:  Blood       Date:  2011-12-08       Impact factor: 22.113

2.  Magnetic resonance imaging as a supplement for the clinical staging system of Durie and Salmon?

Authors:  Andrea Baur; Axel Stäbler; Dorothea Nagel; Rolf Lamerz; Reiner Bartl; Erhard Hiller; Clemens Wendtner; Fridleif Bachner; Maximilian Reiser
Journal:  Cancer       Date:  2002-09-15       Impact factor: 6.860

3.  Diffuse pattern of bone marrow involvement on magnetic resonance imaging is associated with high risk cytogenetics and poor outcome in newly diagnosed, symptomatic patients with multiple myeloma: a single center experience on 228 patients.

Authors:  Lia A Moulopoulos; Meletios A Dimopoulos; Efstathios Kastritis; Dimitrios Christoulas; Maria Gkotzamanidou; Maria Roussou; Andreas Koureas; Magdalini Migkou; Maria Gavriatopoulou; Evangelos Eleutherakis-Papaiakovou; Dimitra Gika; Vasilios Koutoulidis; Evangelos Terpos
Journal:  Am J Hematol       Date:  2012-05-28       Impact factor: 10.047

Review 4.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

5.  Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65/ GMMG-HD4 trial.

Authors:  Pieter Sonneveld; Ingo G H Schmidt-Wolf; Bronno van der Holt; Laila El Jarari; Uta Bertsch; Hans Salwender; Sonja Zweegman; Edo Vellenga; Annemiek Broyl; Igor W Blau; Katja C Weisel; Shulamiet Wittebol; Gerard M J Bos; Marian Stevens-Kroef; Christof Scheid; Michael Pfreundschuh; Dirk Hose; Anna Jauch; Helgi van der Velde; Reinier Raymakers; Martijn R Schaafsma; Marie-Jose Kersten; Marinus van Marwijk-Kooy; Ulrich Duehrsen; Walter Lindemann; Pierre W Wijermans; Henk M Lokhorst; Hartmut M Goldschmidt
Journal:  J Clin Oncol       Date:  2012-07-16       Impact factor: 44.544

6.  Changes in magnetic resonance imaging before and after autologous stem cell transplantation correlate with response and survival in multiple myeloma.

Authors:  Jens Hillengass; Sofia Ayyaz; Kerstin Kilk; Marc-André Weber; Thomas Hielscher; Rajiv Shah; Dirk Hose; Stefan Delorme; Hartmut Goldschmidt; Kai Neben
Journal:  Haematologica       Date:  2012-06-11       Impact factor: 9.941

7.  Role of magnetic resonance imaging in the management of patients with multiple myeloma: a consensus statement.

Authors:  Meletios A Dimopoulos; Jens Hillengass; Saad Usmani; Elena Zamagni; Suzanne Lentzsch; Faith E Davies; Noopur Raje; Orhan Sezer; Sonja Zweegman; Jatin Shah; Ashraf Badros; Kazuyuki Shimizu; Philippe Moreau; Chor-Sang Chim; Juan José Lahuerta; Jian Hou; Artur Jurczyszyn; Hartmut Goldschmidt; Pieter Sonneveld; Antonio Palumbo; Heinz Ludwig; Michele Cavo; Bart Barlogie; Kenneth Anderson; G David Roodman; S Vincent Rajkumar; Brian G M Durie; Evangelos Terpos
Journal:  J Clin Oncol       Date:  2015-01-20       Impact factor: 44.544

8.  Magnetic resonance imaging of the spine in multiple myeloma.

Authors:  H Ludwig; F Frühwald; D Tscholakoff; S Rasoul; A Neuhold; E Fritz
Journal:  Lancet       Date:  1987-08-15       Impact factor: 79.321

9.  Contrast enhanced MRI and ¹⁸F-FDG PET-CT in the assessment of multiple myeloma: a comparison of results in different phases of the disease.

Authors:  P Spinnato; A Bazzocchi; A Brioli; C Nanni; E Zamagni; U Albisinni; M Cavo; S Fanti; G Battista; E Salizzoni
Journal:  Eur J Radiol       Date:  2012-08-24       Impact factor: 3.528

10.  Predictive value of longitudinal whole-body magnetic resonance imaging in patients with smoldering multiple myeloma.

Authors:  M Merz; T Hielscher; B Wagner; S Sauer; S Shah; M S Raab; A Jauch; K Neben; D Hose; G Egerer; M A Weber; S Delorme; H Goldschmidt; J Hillengass
Journal:  Leukemia       Date:  2014-02-18       Impact factor: 11.528

View more
  14 in total

1.  Dual-energy CT of the bone marrow in multiple myeloma: diagnostic accuracy for quantitative differentiation of infiltration patterns.

Authors:  Aleksander Kosmala; Andreas Max Weng; Bernhard Krauss; Stefan Knop; Thorsten Alexander Bley; Bernhard Petritsch
Journal:  Eur Radiol       Date:  2018-06-07       Impact factor: 5.315

2.  The presence of large focal lesions is a strong independent prognostic factor in multiple myeloma.

Authors:  Leo Rasche; Edgardo J Angtuaco; Terri L Alpe; Grant H Gershner; James E McDonald; Rohan S Samant; Manoj Kumar; Rudy Van Hemert; Joshua Epstein; Shayu Deshpande; Ruslana Tytarenko; Shmuel Yaccoby; Jens Hillengass; Sharmilan Thanendrarajan; Carolina Schinke; Frits van Rhee; Maurizio Zangari; Brian A Walker; Bart Barlogie; Gareth J Morgan; Faith E Davies; Niels Weinhold
Journal:  Blood       Date:  2018-05-21       Impact factor: 22.113

Review 3.  High-risk disease in newly diagnosed multiple myeloma: beyond the R-ISS and IMWG definitions.

Authors:  Patrick Hagen; Jiwang Zhang; Kevin Barton
Journal:  Blood Cancer J       Date:  2022-05-30       Impact factor: 9.812

4.  [Focal lesions in whole-body MRI in multiple myeloma : Quantification of tumor mass and correlation with disease-related parameters and prognosis].

Authors:  S C Brandelik; J Krzykalla; T Hielscher; J Hillengass; J K Kloth; H U Kauczor; M A Weber
Journal:  Radiologe       Date:  2018-01       Impact factor: 0.635

5.  18F-fluorocholine versus 18F-fluorodeoxyglucose for PET/CT imaging in patients with suspected relapsing or progressive multiple myeloma: a pilot study.

Authors:  Thibaut Cassou-Mounat; Sona Balogova; Valérie Nataf; Marie Calzada; Virginie Huchet; Khaldoun Kerrou; Jean-Yves Devaux; Mohamad Mohty; Jean-Noël Talbot; Laurent Garderet
Journal:  Eur J Nucl Med Mol Imaging       Date:  2016-04-28       Impact factor: 9.236

6.  Association between magnetic resonance imaging patterns and baseline disease features in multiple myeloma: analyzing surrogates of tumour mass and biology.

Authors:  Elias K Mai; Thomas Hielscher; Jost K Kloth; Maximilian Merz; Sofia Shah; Michaela Hillengass; Barbara Wagner; Dirk Hose; M S Raab; Anna Jauch; Stefan Delorme; Hartmut Goldschmidt; Marc-André Weber; Jens Hillengass
Journal:  Eur Radiol       Date:  2016-01-15       Impact factor: 5.315

7.  Whole body magnetic resonance imaging in newly diagnosed multiple myeloma: early changes in lesional signal fat fraction predict disease response.

Authors:  Arash Latifoltojar; Margaret Hall-Craggs; Neil Rabin; Rakesh Popat; Alan Bainbridge; Nikolaos Dikaios; Magdalena Sokolska; Ali Rismani; Shirley D'Sa; Shonit Punwani; Kwee Yong
Journal:  Br J Haematol       Date:  2016-10-21       Impact factor: 6.998

8.  Quantitative whole-body MR imaging for assessment of tumor burden in patients with multiple myeloma: correlation with prognostic biomarkers.

Authors:  Mengtian Sun; Jingliang Cheng; Cuiping Ren; Yong Zhang; Yinhua Li; Ying Li; Suping Zhang
Journal:  Quant Imaging Med Surg       Date:  2021-08

9.  Whole Body Low Dose Computed Tomography (WBLDCT) Can Be Comparable to Whole-Body Magnetic Resonance Imaging (WBMRI) in the Assessment of Multiple Myeloma.

Authors:  Davide Ippolito; Teresa Giandola; Cesare Maino; Davide Gandola; Maria Ragusi; Pietro Andrea Bonaffini; Sandro Sironi
Journal:  Diagnostics (Basel)       Date:  2021-05-11

10.  Whole-body diffusion-weighted MRI: a new gold standard for assessing disease burden in patients with multiple myeloma?

Authors:  C Pawlyn; L Fowkes; S Otero; J R Jones; K D Boyd; F E Davies; G J Morgan; D J Collins; B Sharma; A Riddell; M F Kaiser; C Messiou
Journal:  Leukemia       Date:  2015-12-09       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.